Volume | 464,063 |
|
|||||
News | (1) | ||||||
Day High | 8.5899 | Low High |
|||||
Day Low | 8.17 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Mind Medicine MindMed Inc | MNMD | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
8.30 | 8.17 | 8.5899 | 8.46 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,659 | 464,063 | $ 8.35 | $ 3,873,358 | - | 2.41 - 12.22 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
11:44:13 | 3 | $ 8.44 | USD |
Mind Medicine MindMed (MNMD) Options Flow Summary
Mind Medicine MindMed Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.89M | 41.33M | - | 0 | -95.73M | -2.32 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Mind Medicine MindMed News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MNMD Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 9.60 | 9.66 | 8.17 | 8.75 | 1,207,972 | -1.16 | -12.08% |
1 Month | 9.52 | 12.22 | 8.17 | 10.25 | 1,722,387 | -1.08 | -11.34% |
3 Months | 3.90 | 12.22 | 3.82 | 8.80 | 2,396,607 | 4.54 | 116.41% |
6 Months | 2.71 | 12.22 | 2.41 | 7.66 | 1,416,243 | 5.73 | 211.44% |
1 Year | 3.72 | 12.22 | 2.41 | 6.73 | 937,599 | 4.72 | 126.88% |
3 Years | 85.3005 | 86.55 | 2.12 | 27.83 | 3,268,501 | -76.86 | -90.11% |
5 Years | 85.3005 | 86.55 | 2.12 | 27.83 | 3,268,501 | -76.86 | -90.11% |
Mind Medicine MindMed Description
Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies. |